Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- CoreWeave stock drops on dilution fears and debt concerns
- Wall Street ends lower, off record highs, as Treasury yields climb
Kala Pharmaceuticals (KALA) Reports In-Line Q1 EPS, Revenues Beat
May 9, 2019 7:25 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q1 EPS of ($0.75), in-line with the analyst estimate of ($0.75). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $1.1 million.
We are pleased with our results during the first quarter of 2019, particularly as it... More



